News

TransGen Receives CE Mark for Trans SARS-CoV-2 & Influenza A/B Assay

Time:2020-11-30 08:30:26 View:

TransGen proudly announces that Trans SARS-CoV-2 & Influenza A/B Assay (Cat. No. DV102) is CE marked, which means this product has been cleared for distribution to the European Union (EU) common market or other countries that recognize CE marking .


TransGen Receives CE Mark for Trans SARS-CoV-2 & Influenza A/B Assay


The CE marked Trans SARS-CoV-2 & Influenza A/B Assay is a real-time RT-PCR multiplexed test intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, Influenza A virus and Influenza B virus. It allows healthcare providers to quickly identify patients with Influenza A/B and differentiate those with COVID-19, using one single test, which will highly improve the efficiency for COVID-19 diagnosis.

 

TransGen’s Efforts to the Fight against SARS-CoV-2

Since the outbreak of COVID-19, TransGen has developed a broad portfolio for SARS-CoV-2 Detection solutions. Most of them have received CE mark, including SARS-CoV-2 Nucleic Acid Detection Kit (Multiplex Real Time RT-PCR), Trans SARS-CoV-2 & Influenza A/B Assay for the detection and differentiation of SARS-CoV-2 and Influenza A/B, TransGuard Disposable Virus Sampling Tube for sample collection, and EasyPure® Viral DNA/RNA Kit, MagicPure® 32 Viral DNA/RNA Kit and MagicPure® 96 Viral DNA/RNA Kit for RNA extraction. As the global battle against SARS-CoV-2 continues, we will persist in the efforts to the fight against the pandemic.

 

Related Pages

One-stop SARS-CoV-2 Detection Solutions

One Stop from Viral Nucleic Acid Extraction to Detection


Message